- Home
- SQFT vs KPRX Comparison
SQFT vs KPRX Comparison
Compare SQFT & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SQFT
- KPRX
- Stock Information
- Founded
- SQFT 1999
- KPRX 1998
- Country
- SQFT United States
- KPRX United States
- Employees
- SQFT N/A
- KPRX N/A
- Industry
- SQFT Real Estate Investment Trusts
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- SQFT Real Estate
- KPRX Health Care
- Exchange
- SQFT Nasdaq
- KPRX Nasdaq
- Market Cap
- SQFT 7.7M
- KPRX 9.2M
- IPO Year
- SQFT 2020
- KPRX N/A
- Fundamental
- Price
- SQFT $6.16
- KPRX $2.53
- Analyst Decision
- SQFT
- KPRX Strong Buy
- Analyst Count
- SQFT 0
- KPRX 1
- Target Price
- SQFT N/A
- KPRX $10.00
- AVG Volume (30 Days)
- SQFT 43.1K
- KPRX 48.4K
- Earning Date
- SQFT 11-11-2025
- KPRX 11-07-2025
- Dividend Yield
- SQFT N/A
- KPRX N/A
- EPS Growth
- SQFT N/A
- KPRX N/A
- EPS
- SQFT N/A
- KPRX N/A
- Revenue
- SQFT $18,052,597.00
- KPRX N/A
- Revenue This Year
- SQFT $23.63
- KPRX N/A
- Revenue Next Year
- SQFT N/A
- KPRX N/A
- P/E Ratio
- SQFT N/A
- KPRX N/A
- Revenue Growth
- SQFT N/A
- KPRX N/A
- 52 Week Low
- SQFT $4.19
- KPRX $2.21
- 52 Week High
- SQFT $23.00
- KPRX $4.18
- Technical
- Relative Strength Index (RSI)
- SQFT 56.07
- KPRX 45.20
- Support Level
- SQFT $5.68
- KPRX $2.21
- Resistance Level
- SQFT $6.34
- KPRX $2.68
- Average True Range (ATR)
- SQFT 0.35
- KPRX 0.16
- MACD
- SQFT 0.04
- KPRX -0.02
- Stochastic Oscillator
- SQFT 81.08
- KPRX 50.00
About SQFT Presidio Property Trust Inc.
Presidio Property Trust Inc is an internally managed, diversified REIT with holdings in model home properties which are triple-net leased to homebuilders, office, industrial, and retail properties. Presidio's model homes are leased to homebuilders located in Arizona, Illinois, Texas, Wisconsin, and Florida. The office, industrial and retail properties are located in Colorado, with properties also located in Maryland, North Dakota, Texas, and Southern California.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.